Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood Sample Storage Evaluated for PEA Analysis

By LabMedica International staff writers
Posted on 29 May 2017
A team of Swedish researchers evaluated and optimized conditions for storing samples of dried blood for current and future proximity extension assay (PEA) analysis.

Dried blood samples are attractive for sample preservation due to the ease and low cost of collection and storage. More...
In a recent study, investigators at Uppsala University evaluated their suitability for protein measurements. The investigators analyzed 92 proteins with relevance for oncology using multiplex proximity extension assays (PEA) in dried blood spots collected on paper and stored for up to 30 years at either plus four degrees Celsius or minus 24 degrees Celsius.

According to the PEA method, a pair of oligonucleotide-labeled antibodies is allowed to pair-wise bind to the target protein present in the dried-blood sample in a homogeneous assay, with no need for washing. When the two probes are in close proximity, a new PCR target sequence is formed by a proximity-dependent DNA polymerization event. The resulting sequence is subsequently detected and quantified using standard real-time PCR. This method, which has been commercialized under the name Proseek Multiplex by Olink, allows detection of levels of 96 proteins (including four controls) from a disc 1.2 millimeters in diameter punched out of a dried blood spot (DBS) on filter paper.

The main findings of the study were that (1) the act of drying only slightly influenced detection of blood proteins in a reproducible manner, (2) detection of some proteins was not significantly affected by storage over the full range of three decades (34% and 76% of the analyzed proteins at plus four degrees Celsius and minus 24 degrees Celsius, respectively), while levels of others decreased slowly during storage with half-lives in the range of 10 to 50 years, and (3) detectability of proteins was less affected in dried samples stored at minus 24 degrees Celsius compared to at four degrees Celsius.

"This has several implications. First, you can prick your own finger and send in a dried blood spot by post. Second, at a minimal cost, it will be possible to build gigantic biobanks of samples obtained on a routine clinical basis. This means that samples can be taken before the clinical debut of a disease, to identify markers of value for early diagnosis, improving the scope for curative treatment," said senior author Dr. Ulf Landegren, professor of molecular medicine at Uppsala University.

The study was published in the May 13, 2017, online edition of the journal Molecular & Cellular Proteomics.


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.